» Articles » PMID: 36918880

Determinants and Economic Burden of HIV/AIDS in Iran: a Prospective Study

Overview
Publisher Biomed Central
Specialty Health Services
Date 2023 Mar 15
PMID 36918880
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Since the start of the AIDS outbreak, the human immunodeficiency virus (HIV) has infected about 84.2 million people, and approximately 40.1 million people have died due to AIDS-related diseases. So, this study aims to provide a comprehensive population-based description of patient costs and the economic burden of HIV/AIDS in Iran.

Methods: The study population of this cross-sectional cost-of-illness study consisted of HIV-infected patients who were receiving services in Mashhad and were under the supervision of BIDCC. There are four BIDCC centers in Mashhad, we considered all patients referred to these centers. Costs data were evaluated from a social perspective with a bottom-up approach and as a prevalence based. The data from 157 individuals were included in the study. For collecting data on direct and indirect costs belonging to patients and their families, a questionnaire was developed. Also, the Demographic characteristic of participants and the stage of the disease and Transmission category were analyzed.

Results: In this study, 57.32 of the subjects were Male. The majority of participants in this study were in the age group 30-59 years (n = 124,78.98%). Based on where the patients live, the majority of patients have lived in the urban region (n = 144, 91.72%). The most common way to transmit this disease is through unprotected sex (30.57%) and then Infected spouse (28.03%), and then injecting drugs (21.02%). The highest cost of this disease is attributed to medicine (10339.32 $ for 6 months), after medicine, the cost of tests was 9101.22 $.

Conclusion: It seems that to reduce costs for patients with disease HIV/AIDS, the focus should be on diagnostic tests and care. Early diagnosis and rapid initiation of antiviral treatments can be effective in preventing serious and debilitating diseases.

Citing Articles

Sero-prevalence of Hepatitis B and C Viruses in Municipal Waste Collectors in Southwest of Iran.

Al-Mendalawi M Indian J Occup Environ Med. 2024; 28(3):255.

PMID: 39618899 PMC: 11606554. DOI: 10.4103/ijoem.ijoem_212_23.


Antimicrobial susceptibility patterns of urinary tract infections causing bacterial isolates and associated risk factors among HIV patients in Tigray, Northern Ethiopia.

Kahsay T, Gebrehiwot G, Gebreyohannes G, Tilahun M, Gessese A, Kahsay A BMC Microbiol. 2024; 24(1):148.

PMID: 38678188 PMC: 11055276. DOI: 10.1186/s12866-024-03297-2.


Association between psychological discomforts and sleep quality among people living with HIV/AIDS.

Mousavi M, Nejad S, Shafaati M, Mykyta-Chomsky R, Akbarpour S, Hadavandsiri F AIDS Res Ther. 2023; 20(1):78.

PMID: 37951932 PMC: 10638710. DOI: 10.1186/s12981-023-00579-z.

References
1.
Beck E, Harling G, Gerbase S, DeLay P . The cost of treatment and care for people living with HIV infection: implications of published studies, 1999-2008. Curr Opin HIV AIDS. 2010; 5(3):215-24. DOI: 10.1097/COH.0b013e32833860e9. View

2.
Kuhlmann J, Keaei M, Conde R, Evers S, Gonzalez J, Govers M . A Cost-of-Illness Study of Patients with HIV/AIDS in Bogotá, Colombia. Value Health Reg Issues. 2017; 14:103-107. DOI: 10.1016/j.vhri.2017.09.002. View

3.
Poudel A, Newlands D, Simkhada P . The economic burden of HIV/AIDS on individuals and households in Nepal: a quantitative study. BMC Health Serv Res. 2017; 17(1):76. PMC: 5259845. DOI: 10.1186/s12913-017-1976-y. View

4.
Roehrborn C, Albertsen P, Stokes M, Black L, Benedict A . First-year costs of treating prostate cancer: estimates from SEER-Medicare data. Prostate Cancer Prostatic Dis. 2009; 12(4):355-60. DOI: 10.1038/pcan.2009.21. View

5.
. Global, regional, and national incidence, prevalence, and mortality of HIV, 1980-2017, and forecasts to 2030, for 195 countries and territories: a systematic analysis for the Global Burden of Diseases, Injuries, and Risk Factors Study 2017. Lancet HIV. 2019; 6(12):e831-e859. PMC: 6934077. DOI: 10.1016/S2352-3018(19)30196-1. View